BioSpace News Archive

Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the closing of its initial public offering of 8,984,375 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,171,875 additional shares of common stock, at a public offering price of $16.00 per share.

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the closing of its initial public offering of 12,650,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,650,000 additional shares of its common stock, at the public offering price of $16.00 per share

Astrotech Corporation announced that its Astrotech Technologies, Inc. subsidiary has entered into an agreement with Sanmina Corporation to manufacture its mass spectrometry products.

SOC Telemed, Inc. (Nasdaq: TLMD), the largest national provider of acute care telemedicine, today announced a major acquisition and its results for the fourth quarter and full year ending December 31, 2020.

Baxter International Inc., a leading global medical products company, announced that, due to the public health and safety concerns related to the novel coronavirus pandemic, its Annual Meeting of Stockholders will again be held by means of a virtual format only.

The American Diabetes Association is pleased to announce the launch of the Better Choices for Life program. The program is designed to aid shoppers in making better choices while shopping and is currently in its pilot stage.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2020 and provided an update on key highlights for 2021.

DD01 is a long-acting dual agonist of GLP-1 and glucagon receptors, which resulted in weight loss, improved metabolic control and reduced fatty liver in animal models of human disease.

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Christopher Wright, M.D., Ph.D., as Chief Medical Officer.

Fourth Quarter Revenues of $3.59 million and Full Year 2020 Revenues of $10.13 million PolarityTE to host conference call and webcast today, March 30, 2021 at 8:00 a.m. ET